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Abstract
We report the updated classification of Inborn Errors of Immunity/Primary Immunodeficiencies, compiled by the International
Union of Immunological Societies Expert Committee. This report documents the key clinical and laboratory features of 430
inborn errors of immunity, including 64 gene defects that have either been discovered in the past 2 years since the previous update
(published January 2018) or were characterized earlier but have since been confirmed or expanded upon in subsequent studies.
The application of next-generation sequencing continues to expedite the rapid identification of novel gene defects, rare or
common; broaden the immunological and clinical phenotypes of conditions arising from known gene defects and even known
variants; and implement gene-specific therapies. These advances are contributing to greater understanding of the molecular,
cellular, and immunological mechanisms of disease, thereby enhancing immunological knowledge while improving the man-
agement of patients and their families. This report serves as a valuable resource for the molecular diagnosis of individuals with
heritable immunological disorders and also for the scientific dissection of cellular and molecular mechanisms underlying inborn
errors of immunity and related human diseases.
Keywords IUIS . primary immune deficiency . inborn errors of immunity . immune dysregulation . autoinflammatory disorders .
next-generation sequencing
Inborn errors of immunity, also referred to as primary immu-
nodeficiencies, manifest as increased susceptibility to infec-
tious diseases, autoimmunity, autoinflammatory diseases, al-
lergy, and/or malignancy. These conditions are caused by
monogenic germline mutations that result in loss of expres-
sion, loss-of-function (LOF; amorphic/hypomorphic), or gain-
of-function (GOF; hypermorphic) of the encoded protein [1,
2]. Heterozygous lesions may underlie autosomal dominant
traits by GOF, haploinsufficiency, or negative dominance.
Biallelic lesions typically cause autosomal recessive traits by
LOF of the encoded protein (rarely GOF), while X-linked
recessive traits arise from LOF of genes on the X chromosome,
either in the hemizygous state in males or in the homozygous
state in females. Rare X-linked dominant traits can also arise
from LOF or GOF variants. This results in aberrant immunity
due to the critical roles of these proteins in the development,
maintenance and function of cells of the immune system, or
cells other than leukocytes that contribute to immunity, during
homeostasis and in response to external (e.g., infectious agents
or environmental antigens) and internal (e.g., cytokines, self-
antigens and cancer cells) stimuli [3–5]. Inborn errors of immu-
nity were traditionally considered to be rare diseases, affecting
~ 1 in 10,000 to 1 in 50,000 births. However, with ongoing
discovery of novel inborn errors of immunity (Fig. 1a) and
improved definition of clinical phenotypes [6–8], the collective
prevalence of these conditions is more likely to be at least 1/
1000–1/5000 [9]. Indeed, more common inborn errors have
recently been described [10]. Regardless of their exact inci-
dence and prevalence, inborn errors of immunity represent an
unprecedented model to link defined monogenic defects with
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clinical phenotypes of immune dysregulation, in a broad sense
of the term. As a committee, we are aware that human immu-
nity involves cells other than circulating or tissue leukocytes
and that it can be scaled up from the immune system to the
whole organism. Inborn errors of immunity have unequivocally
revealed non-redundant roles of single genes and their products
in immune function [3, 4, 6–8], formed the basis of improved
mechanism-based therapies for the immunopathology underly-
ing many diseases [8, 11], established immunological para-
digms representing the foundations of basic, clinical and trans-
lational immunology [3–5, 9, 12–14], and provided insights
into the molecular pathogenesis of more common diseases [9,
15]. Clear examples of these include:
& The initial description by Bruton of X-linked agamma-
globulinemia (XLA) and the ability to treat this condition
with antibody replacement therapy (the mainstay treat-
ment for antibody deficiency diseases such as CVID) [16]
& The discovery of mutations in BTK [12] and the subse-
quent development of BTK-inhibitors such as ibrutinib for
the treatment of B cell malignancies [14]
& Progressive CD4 T cell deficiency explains opportunistic
infections secondary to HIV infection [9].
Thus, the study of inborn errors of immunity has provided
profound advances in the practice of precision molecular
medicine.
Since the early 1950s, when XLA was one of the first
primary immune deficiencies to be described [16], clinical
immunology has leveraged advances in the development of
new methods to expedite the identification of defects of the
immune system and the cellular, molecular, and genetic aber-
rations underlying these conditions. Indeed, the completion of
the Human Genome Project in the early 2000s, coupled with
rapid developments in next generation DNA sequencing
(NGS) technologies, enabled the application of cost-effective
and time-efficient sequencing of targeted gene panels, whole
exomes, or whole genomes to cohorts of patients suspected of
having a monogenic explanation for their disease. These plat-
forms have led to a quantum leap in the identification and
diagnosis of previously undefined genetically determined de-
fects of the immune system (Fig. 1a, b; [6–8]).
The International Union of Immunological Societies
Expert Committee of Inborn Errors of Immunity comprises
pediatric and adult clinical immunologists, clinician/scientists
and researchers in basic immunology from across the globe
(https://iuis.org/committees/iei/). A major objective and
responsibility of the committee is to provide the clinical and
research communities with an update of genetic causes of
immune deficiency and dysregulation. The committee has
existed since 1970 and has published an updated report
approximately every 2 years to inform the field of these
advances (Fig. 1a). In March 2019, the committee met in
New York to discuss and debate the inclusion of genetic
variants published over the preceding 2 years (since June
2017) [1, 2], as well as gene mutations that had appeared in
the literature earlier but, based on newly available evidence,
were now substantiated (Fig. 1b).
Rather than simply including every gene variant reported,
the committee applies very stringent criteria such that only
those genes with convincing evidence of disease pathogenic-
ity are classified as causes of novel inborn errors of immunity
[17]. The Committee makes informed judgments for including
new genetic causes of immunological conditions based on
what we believe is most useful for practitioners caring for
patients. Our current, and continuously evolving, practice is
that criteria for inclusion can be met by several ways, for
Fig. 1 Rate of discovery of novel inborn errors of immunity: 1983–2019.
a The number of genetic defects underlying monogenic immune
disorders as reported by the IUIS/WHO committee in the indicated
year. b The number of pathogenic gene variants listed in each table by
the IUIS committee. Report published in 2017, and the number of new
genes for each table contained in this report (red bars). The numbers in
each column correspond to the number of genes reported in the 2017 IUIS
update (blue bars) [1, 2], the number of new genes for each table
contained in this report (red bars), and the total number of genes for
each table. Note: only data for Tables 1, 2, 3, 4, 5, 6, 7, and 8 are
shown, because Table 9 (bone marrow failure) is a new addition to the
current report.
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instance peer-reviewed publication of (1) multiple cases
from unrelated kindreds, including detailed immunologic
data, or (2) very few cases, or even a single case (see
below), for whom compelling mechanistic/pathogenic data
is also provided, generally from parallel studies in an ani-
mal or cell culture model.
Herein, we provide this latest update. The inborn errors
of immunity are listed in 10 tables: Combined immunode-
ficiencies (Table 1), Combined immunodeficiencies with
syndromic features (Table 2), Predominantly antibody de-
ficiencies (Table 3), Diseases of immune dysregulation
(Table 4), Congenital defects of phagocytes (Table 5),
Defects in intrinsic and innate immunity (Table 6),
Autoinflammatory diseases (Table 7), Complement defi-
ciencies (Table 8), and Phenocopies of inborn errors of
immunity (Table 10) (Fig. 1b). Since the last update (pub-
lished January 2018) [1, 2], we have added a new table to
consolidate genes that cause bone marrow failure (Table
9). Our division into phenotypes does not imply that the
presentation is homogeneous. Rather, we recognize that
substantial phenotypic and clinical heterogeneity exists
within groups of patients with mutations in the same gene
and even between individuals from the same pedigree with
the identical gene mutation. To simplify the classification,
each disorder has been listed only once, although distinct
disorders due to mutations in the same gene, but with dif-
ferent modes of inheritance and pathogenic mechanisms
are listed individually. Thus, several genes appear more
than once in this update (some examples are listed below).
Sub-divisions within each table segregate groups of disor-
ders into coherent phenotypic sets. OMIM numbers are
also provided within each table. If a OMIM number has
not yet been issued for a particular genetic condition, then
the number provided generally refers to the OMIM for that
gene. Beneath each table, the new disorders added to this
update are highlighted for easy reference.
The advances in our understanding of clinical immunol-
ogy continue to expand at a vast and remarkable rate, with
the addition in this update of many—64, distributed across
all tables (Fig. 1b)—novel genetic defects underlying in-
born errors of immunity. Perhaps not surprisingly, most if
not all of these new variants were identified by NGS, thus
highlighting that whole exome/whole genome sequencing
has become the gold standard for identifying novel patho-
genic gene variants [6–8]. Indeed, since the first applica-
tion of NGS to identify novel inborn errors of immunity
was published in 2010 [18], ~ 45% of all currently known
disease-causing variants have been discovered by whole
exome/genome sequencing. Thus, a typical approach to
identifying a pathogenic variant in a new patient might
now consist of first sequencing a phenotype-driven panel
of genes and advancing to whole exome/genome sequenc-
ing if the cause of disease remains elusive.
In this update, we increase the list of immunological
diseases to 404, with 430 known genetic defects identified
as causing these conditions. The unbiased application of
NGS to the discovery and characterization of novel inborn
errors of immunity continues to inform clinical and basic
immunology. Thus, additional phenotypes have been
identified for conditions resulting from variants in known
and novel genes; the penetrance of genetic variants on
clinical phenotypes has been shown to be highly variable;
and clinical entities sharing common phenotypes have
been discovered. For example, this update includes the
findings that bi-allelic mutations in ZNF341 [19, 20],
IL6ST (encoding gp130, a common component of the re-
ceptors for IL-6, IL-11, IL-27, LIF, OSM, CNTF) [21,
22], or IL6R [23, 24] all cause conditions that resemble
autosomal dominant hyper-IgE syndrome due to dominant
negative mutations in STAT3 [15]. Detailed analyses of
these patients revealed a novel mechanism of regulating
STAT3 signaling (via the transcription factor ZNF341)
and defined the exact consequences of impaired IL-6/IL-
6R/gp130 and putatively IL-11/IL-11R/gp130 signaling to
the phenotype of AD-HIES.
Furthermore, key findings over the past 2 years contin-
ue to reveal that distinct mechanisms of disease (GOF,
LOF, dominant negative, haploinsufficient), as well as
different modes of inheritance (autosomal recessive, auto-
somal dominant) of variants in the same gene can cause
disparate clinical conditions. This is a fascinating aspect
of the genetics of human disease, and a salient reminder
to be cognizant of the nature of the genetic variants iden-
tified from NGS. It is these genes that have several entries
in this update. A few recent examples include:
1. Heterozygous variants in CARD11 [25, 26] or STAT5B
[27] can be pathogenic due to negative dominance. This
was potentially unexpected because autosomal recessive
LOF variants in both of these genes were previously re-
ported to cause combined immunodeficiency and severe
immune dysregulation, respectively, yet heterozygous rel-
atives of these affected individuals were healthy [28, 29].
2. While heterozygous dominant negative mutations in
TCF3, encoding the transcription factor E47, cause B cell
deficiency and agammaglobulinemia [30], nonsense mu-
tations in TCF3 have now been identified that are patho-
genic only in an autosomal recessive state, as heterozy-
gous carriers of these particular allelic variants remained
healthy [31, 32].
3. A heterozygous hypermorphic variant in IKBKB was
found to cause a combined immunodeficiency [33] not
too dissimilar to the original description of bi-allelic, re-
cessive variants in IKBKB [34]. Similarly, bi-allelic LOF
mutations in PIK3CD are now known to cause B cell
deficiency and agammaglobulinemia [35–37], which is
J Clin Immunol (2020) 40:24–6426
quite distinct from the immune dysregulated state of indi-
viduals with monoallelic activating PIK3CD mutations
[1, 37]. This observation nicely parallels the earlier find-
ings of either homozygous or heterozygous mutations in
PIK3R1 that clinically phenocopy recessive or activating
mutations in PIK3CD respectively [1, 37].
4. Distinct diseases can result from heterozygous mutations
in IKZF1 (Ikaros): combined immunodeficiency due to
dominant negative alleles [38] or CVID due to
haploinsufficiency [39].
5. Similar to STAT1 [40], variants in RAC2 [41–45] or
CARD11 [25, 26, 28] can be pathogenic either as
monoallelic GOF or LOF or bi-allelic recessive LOF.
Thus, these findings have revealed the fundamental im-
portance of elucidating the impact of a novel variant on the
function of the encoded protein and thus the mechanism of
pathogenicity. Furthermore, these new entries are an im-
portant reminder not to overlook the potential significance
of identifying heterozygous variants in genes previously
believed to cause disease only in a biallelic manner or to
result in a previously defined specific clinical entity.
Indeed, there are now at least 35 genes that have multiple
entries in the current update, reflecting the distinct mecha-
nisms by which variants result in or cause disease (e.g.,
STAT1, STAT3, NLRP1, RAC2, ZAP70, CARD11, IKBKB,
WAS, JAK1, IFIH1, C3, C1R, C1S–GOF or LOF; STAT5,
STAT1, CARD11, ACD, CFH, CFHR1–5, FOXN1, RAC2,
TCF3, AICDA, PIK3R1, IFNGR1, TREX1, TICAM1,
IRF8–AD or AR; PIK3CD–AD GOF, AR LOF; IKZF1–
AD, or haploinsufficient; NLRP3—distinct disease pheno-
types despite all resulting from GOF alleles).
As noted above, genetic, biochemical, and functional
analyses of putative novel pathogenic variants need to
meet stringent criteria to be considered for inclusion in this
update [17]. These criteria can make reporting genetic
findings from single cases challenging, as often the best
evidence that a novel variant is disease-causing is to iden-
tify additional, similarly affected but unrelated individuals
with the same variants, or functionally similar variants in
the same gene. While this can be challenging, particularly
in light of the rarity of individual inborn errors of immu-
nity, robust mechanistic laboratory investigations continue
to provide compelling data from single patients, with or
without evidence from animal models. Specifically, homo-
zygous LOF mutations in IRF9 [46] and IL18BP [47] were
identified and rigorously characterized in single patients
and found to be the molecular cause of life-threatening
influenza and fulminant viral hepatitis, respectively.
The study and discovery of novel inborn errors of im-
munity can also enable improved patient management by
implementing gene-specific targeted therapies. Thus, JAK
inhibitors are being used to treat disorders of immune dys-
regulation resulting from GOF mutations in JAK1, STAT1
or STAT3 [11], while mTOR inhibitors such as rapamycin
or PI3K p110δ-specific inhibitors have been reported for
the treatment of individuals with PIK3CD GOF or PIK3R1
LOF mutations [37]. Regarding novel gene defects, im-
mune dysregulation due to DEF6 deficiency was success-
fully treated with abatacept (CTLA4-Ig) [48]. This corre-
lated with impaired CTLA4 expression and function in
DEF6-deficient T cells [48] and parallels the therapeutic
use of abatacept and belatacept for LRBA-deficiency and
CTLA4 haploinsufficiency, both of which are character-
ized by reduced CTLA4 expression in affected regulatory
T cells [49, 50]. From a theoretical perspective, the finding
that MSMD can be caused by mutations in IL12RB2,
IL23R or SPPL2A and that these mutations are associated
with impaired production of IFNγ—a requisite of anti-my-
cobacterial immunity—implies that IFNγ administration
could be therapeutically beneficial in these clinical settings
[51, 52]. Similarly, recombinant IL18BP could potentially
ameliorate viral-induced liver toxicity due to IL18BP defi-
ciency [47].
The goals of the IUIS Expert Committee on Inborn
Errors of Immunity are to increase awareness, facilitate
recognition, promote optimal treatment, and support re-
search in the field of disorders of immunity. Thus, this
2019 Update and the accompanying “Phenotypical IUIS
Classification” publications are intended as resources for
clinicians and researchers. Importantly, these tables un-
derpin the design of panels used for targeted gene se-
quencing to facilitate genetic diagnoses or inborn errors.
In the past 5 years, the number of gene defects underly-
ing inborn errors of immunity has nearly doubled from ~
250 to 430 (Fig. 1a). The human genome contains 1800–
2000 genes that are known to be involved in immune
responses [13]. Thus, the discovery and study of inborn
errors of immunity has elegantly illustrated that > 20% of
these immune genes play non-redundant roles in host
defense and immune regulation. With the improved iden-
tification and phenotyping of patients with rare diseases,
combined with high throughput genome sequencing, the
number of genes fundamentally required for immunity
will no doubt continue to increase, further revealing crit-
ical and novel roles for specific genes, molecules, path-
ways and cell types in immune responses, as well as
mechanisms of disease pathogenesis and targets for im-
munotherapies. The field of inborn errors of immunity,
and the global clinical and research communities, will
therefore continue to provide key insights into basic and
clinical immunology.
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